Form 4: Apollomics Director Jan Chen-Huan Exercises RSU Vesting

Director Jan Chen-Huan acquired 500 Class A Ordinary Shares of Apollomics Inc. through the vesting of restricted stock units.

Summary

• Director Jan Chen-Huan acquired 500 Class A Ordinary Shares on June 15, 2026.
• The acquisition resulted from the vesting of 500 Restricted Stock Units (RSUs).
• The transaction price for the vested shares was $0.
• Following this transaction, the director holds a total of 1,500 Class A Ordinary Shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a routine administrative update regarding director equity compensation rather than a change in strategic direction or financial performance.

Positives

• Director increased direct equity ownership in the company.
• The transaction reflects the scheduled vesting of previously granted equity compensation.

Negatives

• None identified; this is a routine equity compensation event.

Risks

• None identified; this is a standard administrative filing regarding director compensation.

Future Outlook

The filing notes that an additional 500 shares are scheduled to vest on September 15, 2026.

Industry Context

StockSavvy.ai notes that routine RSU vesting for directors is a standard corporate governance practice in the biotechnology sector, signaling alignment between management and shareholder interests.

Comparison to Industry Standards

• The transaction follows standard equity compensation structures common among publicly traded biotech firms.
• The reporting of RSU vesting is consistent with SEC Section 16(a) disclosure requirements.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard equity compensation vesting event.

Next Steps

• Scheduled vesting of 500 additional RSUs on September 15, 2026.

Key Dates

Keywords

Apollomics, APLM, Form 4, Insider Trading, Equity Vesting, Director Ownership